Head of Assay Biology & Scientific Liaison
Dr. Segaliny is a founding scientist of Amberstone Biosciences. She currently serves as the Head of Assay Biology and Scientific Liaison, where she has spearheaded efforts in developing platform biology to enable the discovery of transformative immunotherapeutics. She has over 10 years of experience in cell-based assays, cancer biology and immunology.
Founder & CEO
Founder & Chief Executive Officer (CEO),ImmuneBiotech. Exploring ways to induce termination of chronic inflammatory disorders by introducing novel and innovative immunotherapies. Consulting and CRO-related services.
Senior researcher, Lund University
Performed research work in the field of Medical Inflammation Research since 1997 in areas of: Chronic inflammation, Autoimmunity, Microbiology & Probiotics, Cancer & Inflammation.
University lecturer, Lund University. Teaching immunology, for the advance and the basic courses (2001-current). Also started 3 new basic courses in immunology incorporated in different programs.
Specialties: Chronic inflammation, Autoimmune disorders e.g. Multiple Sclerosis, Rheumatoid Arthritis, Type 1 Diabetes and Sjogren´s syndrome, Microbiology and probiotics: health benefits and related anti inflammatory effects, Biological markers, New drug target discovery, Drug delivery technology, Diagnosis, Cancer and inflammation.
Dr Philip Beer is a physician scientist and precision oncology specialist who holds diverse roles across the healthcare, academic and commercial sectors. Philip provides clinical cancer genomics support to healthcare improvement projects, including the NHS, and to drug discovery and development ventures in academia and industry. Philip is part of the International Cancer Genome Consortium (ICGC) management team, the Friends of Cancer Research TMB working group and the forthcoming Precision FDA TMB challenge. These projects are unified by a singular goal of leveraging genomic technologies to improve outcomes for cancer patients, and are underpinned by a portfolio of research focused on linking cancer biology and genomics, delivered through honorary positions at the Sanger Institute, UK, and Mayo Clinic, USA.
Pascal Mayer is a scientific innovator and inventor of various technologies with large market value. His inventions lead to the filing of 12 patent families including the core patents behind the world's leading sequencing technology (Illumina), and biofilm measurement technologies (Biofilm Control). Prior to Alphanosos, key experience included VP drug-discovery at BioFilm Control, CEO at Haploys, CSO at Manteia Predictive Medicine (a spin-off from Serono), and Scientist at Glaxo-Wellcome and later Serono.
Learn from the industry’s top leading professionals. Increase your knowledge and partners under one roof
Drug Targets with Genomic Support: A Genomics-based Strategic Framework for Improving Target Discovery and Accelerating Drug Development
Benefits, limitations, and diversity of AI model in drug and target discovery.
Deep generative autopilot for the real world design of novel lead compound.
Complexity simplified; comprehensive data management for complex world.
The Sponsorship opportunity at Meridian Drug Discovery come with countless benefits.
Meetings, meet with industry's most renowned decision-makers exclusively. Dine and discuss business in a private setting; competitor friendly atmosphere.1
The exhibition, deliver yourself from the irrelevant audience, surround yourself with the right decision-makers in a business-driven environment; choose quality over quantity.3
Presentation, Devote yourself to science, feed the next generation with experience-based knowledge. Grasp the opportunity to apprise yourself and your organization.2
Networking, a new partner, the next funding, is just one introduction away. introduce yourself to the right people in the right place. Initiate a new business relationship by being in the right place at the right time.4